Peter Cabot

Source: https://about.uq.edu.au/experts/72 Parent: https://about.uq.edu.au/faculties-institutes/hmbs/about/leaders

Professor

Peter Cabot

Email: : pcabot@pharmacy.uq.edu.au

Phone: : +61 7 334 61854

Positions

Head of School, Pharmacy and Pharmaceutical Sciences : Faculty of Health, Medicine and Behavioural Sciences

Affiliate of Centre for Innovation in Pain and Health Research (CIPHeR) : Centre for Innovation in Pain and Health Research : Faculty of Health, Medicine and Behavioural Sciences

Overview

Background

Peter Cabot is the Professor and Head of School in the School of Pharmacy. He joined the School staff in this position in 1999 after completing postdoctoral positions at Johns Hopkins University, Baltimore USA, The NIH, Baltimore USA and within the School of Pharmacy at UQ.

The primary focus of my research is on the elucidation of the peripheral mechanisms involved in analgesia associated with inflammation. Key discoveries were made in this field that highlighted the importance of the immune system in inflammatory pain. The results of which were published in the notable journals; JBC, PAIN, Nature Medicine and The Journal of Clinical Investigation.

Read more Read less

Availability

Professor Peter Cabot is: : Available for supervision : Media expert

Fields of research

Clinical sciences Pharmacology and pharmaceutical sciences

Qualifications

Bachelor of Applied Science, Charles Sturt University
Doctor of Philosophy, The University of Queensland

Research interests

Opioids in inflammation

In the area I work as a translational scientist, exploring drug discovery of novel opioids and inflammatory mechanisms as well as developing new alternatives, paring this with translational work into preclinical and clinical studies looking for better outcomes for patients.

Read more Read less - #### Biotransformation of Opioids in Disease

Read more Read less - #### Pain in Inflammatory Diseases

Read more Read less - #### Natural Products Drug Discovery

Read more Read less

Research impacts

Our current research is focussed on novel opioid ligands that target opioid receptors aligned with less addictive properties, bioactivity of endogenous and natural products that may provide insights into better pain therapy or reduction in inflammatory disorders such as sinusitis.

Read more Read less

Works

Search Professor Peter Cabot’s works on UQ eSpace

All (161) Journal Article (92) Other Outputs (5) Conference Publication (63) Book Chapter (1)

2024

Conference Publication

Bivalent peptide agonists targeting peripheral Kappa and Nociceptin heterodimer opioid receptors for the treatment of pain and opioid use disorder

Habib, Muhaimin, Saifuddin, Danial, Robitaille, Mélanie and Cabot, Peter (2024). Bivalent peptide agonists targeting peripheral Kappa and Nociceptin heterodimer opioid receptors for the treatment of pain and opioid use disorder. ASCEPT, APFP & APSA Joint Conference, Melbourne, VIC Australia, 1 - 4 December 2024.

Bivalent peptide agonists targeting peripheral Kappa and Nociceptin heterodimer opioid receptors for the treatment of pain and opioid use disorder

2024

Conference Publication

Targeting peripheral mu and delta heterodimer receptors with bivalent opioid peptides

Zhang, Junkai, Robitaille, Melanie, Saifuddin, Danial, Ross, Benjamin and Cabot, Peter (2024). Targeting peripheral mu and delta heterodimer receptors with bivalent opioid peptides. ASCEPT, APFP & APSA Joint Conference, Melbourne, VIC Australia, 1 - 4 December 2024.

Targeting peripheral mu and delta heterodimer receptors with bivalent opioid peptides

2024

Other Outputs

Peptides and uses thereof

Tupally, Karnaker, Cabot, Peter, Nandkumar, Ajit and Parekh, Harendra (2024). Peptides and uses thereof. EP4175970A1.

Peptides and uses thereof

2024

Journal Article

C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors

Farrell, Scott F., Armfield, Nigel R., Cabot, Peter J., Elphinston, Rachel A., Gray, Paul, Minhas, Gunjeet, Collyer, Martin R. and Sterling, Michele (2024). C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors. The Journal of Pain, 25 (2), 476-496. doi: 10.1016/j.jpain.2023.09.008

C-reactive protein (CRP) is associated with chronic pain independently of biopsychosocial factors

2023

Conference Publication

Leveraging eportfolios to support a learner-centred approach in the Master of Pharmaceutical Industry Practice Program

Cabot, Peter John, Bowker, Shari and Slade, Christine (2023). Leveraging eportfolios to support a learner-centred approach in the Master of Pharmaceutical Industry Practice Program. 2023 Eportfolio Forum: Emerging, Connecting, Sustaining, Darwin, NT, Australia, 11-12 October 2023. Adelaide, SA, Australia: ePortfolios Australia.

Leveraging eportfolios to support a learner-centred approach in the Master of Pharmaceutical Industry Practice Program

2023

Conference Publication

Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency

Saifuddin, D., Lohman, R.-J., Tupally, K., Parekh, H. and Cabot, P. (2023). Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing.

Bivalent kappa-selective opioid peptides with enhanced metabolic stability and potency

2023

Conference Publication

Ivermectin effects on interleukin-6 induced nuclear translocation of STAT3 in a macrophage based cell line

Cabot, Peter, Daniel, Sona and Alawie, Rayan (2023). Ivermectin effects on interleukin-6 induced nuclear translocation of STAT3 in a macrophage based cell line. 81st FIP World Congress Of Pharmacy And Pharmaceutical Sciences, Brisbane, QLD Australia, 24-28 September 2023. PKP Publishing. doi: 10.46542/pe.2023.236.314328

Ivermectin effects on interleukin-6 induced nuclear translocation of STAT3 in a macrophage based cell line

2023

Journal Article

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

Galante, Priscilla, Campos, Gabriel A. A., Moser, Jacqueline C. G., Martins, Danubia B., Dos Santos Cabrera, Marcia P., Rangel, Marisa, Coelho, Luiza C., Simon, Karina S., Amado, Veronica M., de A. I. Muller, Jessica, Koehbach, Johannes, Lohman, Rink-Jan, Cabot, Peter J., Vetter, Irina, Craik, David J., Toffoli-Kadri, Monica C., Monge-Fuentes, Victoria, Goulart, Jair T., Schwartz, Elisabeth F., Silva, Luciano P., Bocca, Anamelia L. and Mortari, Márcia R (2023). Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom. Scientific Reports, 13 (1) 12491, 1-15. doi: 10.1038/s41598-023-38828-w

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

2023

Journal Article

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

Lohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J and Parekh, Harendra S (2023). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. Frontiers in Pharmacology, 14 1150313, 1150313-14. doi: 10.3389/fphar.2023.1150313

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

2023

Journal Article

National wastewater reconnaissance of analgesic consumption in Australia

Ahmed, Fahad, Tscharke, Benjamin, O’Brien, Jake W., Hall, Wayne D., Cabot, Peter J., Sowa, P. Marcin, Samanipour, Saer and Thomas, Kevin V. (2023). National wastewater reconnaissance of analgesic consumption in Australia. Environmental Science and Technology, 57 (4), 1712-1720. doi: 10.1021/acs.est.2c06691

National wastewater reconnaissance of analgesic consumption in Australia

2022

Journal Article

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

Lohman, Rink-Jan, Tupally, Karnaker Reddy, Kandale, Ajit, Cabot, Peter J. and Parekh, Harendra S. (2022). Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy. British Journal of Pharmacology, 180 (1), 129-129. doi: 10.1111/bph.15862

Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy

2022

Journal Article

Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy

Koohi Moftakhari Esfahani, Maedeh, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2022). Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy. Pharmaceutics, 14 (8) 1579, 1-27. doi: 10.3390/pharmaceutics14081579

Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy

2022

Journal Article

β-lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cells

Esfahani, Maedeh Koohi Moftakhari, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2022). β-lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cells. Pharmaceutics, 14 (4) 884, 884. doi: 10.3390/pharmaceutics14040884

β-lactoglobulin-modified mesoporous silica nanoparticles: a promising carrier for the targeted delivery of fenbendazole into prostate cancer cells

2021

Journal Article

Pegylated mesoporous silica nanoparticles (MCM-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells

Esfahani, Maedeh Koohi Moftakhari, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul and Izake, Emad L. (2021). Pegylated mesoporous silica nanoparticles (MCM-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells. Pharmaceutics, 13 (10) 1605, 1605. doi: 10.3390/pharmaceutics13101605

Pegylated mesoporous silica nanoparticles (MCM-41): a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells

2021

Other Outputs

Peptides and uses thereof

Parekh, Harendra, Tupally, Karnaker, Cabot, Peter and Kandale, Ajit (2021). Peptides and uses thereof. 2021300202.

Peptides and uses thereof

2021

Conference Publication

Novel opioid peptides as allosteric modulators of nociception

Saifuddin, Danial, Lohman, Rink-Jan, Tupally, Karnaker Reddy, Parekh, Harendra S. and Cabot, Peter J. (2021). Novel opioid peptides as allosteric modulators of nociception. ASMR medical research week: Queensland virtual symposium, Online, 9-10 June 2021.

Novel opioid peptides as allosteric modulators of nociception

2021

Journal Article

Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy

Esfahani, Maedeh Koohi Moftakhari, Islam, Nazrul, Cabot, Peter J. and Izake, Emad L. (2021). Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy. ACS Biomaterials Science and Engineering, 8 (10) acsbiomaterials.1c00066, 4153-4162. doi: 10.1021/acsbiomaterials.1c00066

Development of Thiabendazole-Loaded Mesoporous Silica Nanoparticles for Cancer Therapy

2021

Journal Article

Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity

Alavi, Seyed Ebrahim, Cabot, Peter J., Raza, Aun and Moyle, Peter M. (2021). Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity. Bioconjugate Chemistry, 32 (4), 810-820. doi: 10.1021/acs.bioconjchem.1c00091

Developing GLP-1 conjugated self-assembling nanofibers using copper-catalyzed alkyne–azide cycloaddition and evaluation of their biological activity

2021

Journal Article

Liquid CO2 formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenem

Raza, Aun, Sime, Fekade Bruck, Cabot, Peter J., Roberts, Jason A., Falconer, James R., Kumeria, Tushar and Popat, Amirali (2021). Liquid CO2 formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenem. ACS Biomaterials Science and Engineering, 7 (5) acsbiomaterials.0c01284, 1836-1853. doi: 10.1021/acsbiomaterials.0c01284

Liquid CO2 formulated mesoporous silica nanoparticles for pH-responsive oral delivery of meropenem

2020

Journal Article

Oral meropenem for superbugs: challenges and opportunities

Raza, Aun, Ngieng, Shih Chen, Sime, Fekade Bruck, Cabot, Peter J., Roberts, Jason A., Popat, Amirali, Kumeria, Tushar and Falconer, James R. (2020). Oral meropenem for superbugs: challenges and opportunities. Drug Discovery Today, 26 (2), 551-560. doi: 10.1016/j.drudis.2020.11.004

Oral meropenem for superbugs: challenges and opportunities

Funding

Past funding

2022 - 2024

Development of small nerve fibre pathology in chronic whiplash-associated disorder (RBWH Foundation Grant administered by MNHHS)

Royal Brisbane and Women's Hospital Foundation

Open grant - 2018

High-throughput ion channel pharmacology